PRWeb The Leader Press Release Distribution
See How PRWeb Works

We're here to help 1-866-640-6397

Login Create Free Account


All Press Releases for December 14, 2003 Subscribe to this News Feed    
 

20 - 30 million people in the United States suffer from acne

On the cutting edge of technology: "ClearLight" uses the Acne PhotoClearing (APC) technology to destroy the most common bacteria that causes acne -- quickly and easily.

---"ClearLight" is a systemic drug-free treatment that avoids the variety of side effects of traditional acne treatments.

Topical treatments like creams irritate the skin while oral antibiotics may have other side effects. These both require three months of therapy and scarring remains an issue. Other dangerous medications can cause severe side effects as birth defects.

"ClearLight" is the only FDA approved technology that destroys the most common bacteria that causes acne.

- No discomfort experienced
- Treatments are fast (a typical session is only 15 minutes) and non-invasive
- Procedure can be performed during patients lunch hour
- Patient can resume normal daily activities as soon as possible
- Short treatment regimen:
(8 treatments over 4 weeks to achieve impressive results)
- Can be used effectively on almost anyone on almost every part of the body

If you have acne and would like more information on treating it with ClearLight, please contact:

New Image Cosmetic Surgery
230 Prospect Place, Suite #350
Coronado, CA 92118
(619) 437-1388

Thank you for your interest.

OPTIONS
Printer Friendly Version
Email this story to a colleague
CONTACT INFORMATION
Kristina Stanbery
NEW IMAGE COSMETIC SURGERY
(858) 405-5310
Email us Here
ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your PRWeb News Management Console.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these release. Our complete disclaimer appears here.